Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies

ISRG Intuitive Surgical SEC Filings & Insider Trading Activity 2026

company
CIK 1035267137 filings
Nasdaq 100
S&P 500

ISRG at a glance

Intuitive Surgical (ISRG, SEC CIK 1035267) filed its latest 10-K annual report on February 3, 2026, a 10-Q quarterly report on October 21, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Intuitive Surgical (ISRG) reported revenue of $10.1 billion (up 20.5% from FY2024) and net income of $2.9 billion. Diluted EPS was $7.87.
  • As of September 30, 2026, 56 institutional investment managers tracked by SignalX reported holding Intuitive Surgical (ISRG) shares worth $54.8 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Brosius Mark on November 20, 2026 of 46 shares at $407.24 per share.
  • In the last 90 days, ISRG insiders reported 0 open-market purchases ($0) and 24 open-market sales ($20.2M) on Form 4, a net sale of $20.2M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$10.1B
+20.5% vs prior year
Insiders · 90 days
0 buys · 24 sells
Net −$20.2M
13F holders
56 funds
$54.8B · −4 vs prior quarter
Latest 8-K
Nov 2, 2026
Item 5.02 · Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Management Discussion & Analysis

  • Tariffs increased cost of revenues by $63.0M in 2025; ongoing tariff impact expected to rise in 2026
  • Installed base: 1,231 da Vinci 5 systems, 377 da Vinci SP systems as of Dec 31, 2025
  • Numerous regulatory clearances in 2024-2026 including FDA approvals for da Vinci 5 multi-port & SP systems for expanded procedures
  • Supply chain stress noted in Q4 2025 did not materially impact operations; elevated interest rates and tariff inflation are risks
  • Expansion in China constrained by government quotas and provincial pricing limits; pricing pressure and procedural volume impact possible

Business Overview

  • Core business: robotic-assisted minimally invasive surgical systems with integrated instruments, accessories, learning, and digital solutions
  • New product emphasis: launched da Vinci 5 system with force feedback, 10,000x computing power of Xi, and My Intuitive+ digital subscription package
  • Strategic shift: expanded digital ecosystem with My Intuitive app, SimNow VR simulator, Case Insights analytics, and Intuitive Hub edge computing
  • Quantitative metric: da Vinci 5 features integrated electrosurgical unit, Integrated Table Motion; new 8mm SureForm 30 Curved-Tip stapler introduced
  • Noteworthy fact: first commercial adoption of augmented reality 3D modeling service for pre-operative planning in kidney, prostate, lung, rectal procedures

Risk Factors

  • UK medical device regulatory changes, new post-market rules effective June 16, 2025, with additional rules expected in 2026 potentially delaying UK market approval
  • China anti-corruption campaign in healthcare since July 2023 causing tender cancellations, reducing system placements in 2025 versus expectations
  • Tariffs on imports from Mexico (manufacturing base for majority of instruments) imposed in 2025 increasing product costs and reducing gross margins
  • Competition from Medtronic plc and Johnson & Johnson focusing on robotic-assisted surgical systems and alternative therapies reducing market share
  • Exposure to US Foreign Corrupt Practices Act, UK Bribery Act compliance risks in OUS operations with increasing business in China and complex local laws

AI summary of the ISRG 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New geopolitical risk: Iran conflict added to Middle East disruptions affecting commodities, supply constraints, and liquidity
  • Market risk: tariffs and export controls may increase raw-material and finished-goods costs
  • Financial risk: cash and equivalents declined to $2,978.1 million from $3,368.0 million
  • Regulatory risk: ASU 2025-05 adoption introduced expected-credit-loss estimation changes, without material financial impact

Management Discussion & Analysis

  • Revenue $3.05B, up 22% YoY from $2.51B, driven by systems revenue growth of 30% to $769M
  • Gross margin 68.4% vs 66.4% YoY; product margin 68.9% vs 66.8%, service margin 65.4% vs 63.8%
  • Best segment systems revenue $769M, up 30%; worst instruments and accessories still grew 18% to $1.80B
  • Cash, equivalents, and investments $6.80B vs $9.03B at December 31, 2025; $2.94B spent on share repurchases
  • Outlook: 2027 pricing actions expected to reduce instruments revenue per procedure 3% to 5%; China pricing reductions begin Q4 2026

AI summary of the ISRG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 2, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expansion from 10 to 11 directors, effective January 1, 2027
  • Aaron Martin appointed as an independent Nasdaq and SEC-qualified director

Item 7.01: Regulation FD Disclosure

  • Press release announces Mr. Martin’s appointment, making the leadership change the filing’s core investor-relevant disclosure
  • Exhibit 99.1 contains the announcement details, including the appointed role and effective date

Item EX-99.1: Item EX-99.1

  • Board appointment effective January 1, 2027: Aaron Martin, Humana President of Insurance, joins Intuitive’s governance
  • Board expands from 10 to 11 members, adding payer, healthcare technology, and digital health expertise
Filed Oct 20, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results announced for quarter ended September 30, 2026
  • Detailed financial results furnished in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $3.05B, up 22%, led by instruments and accessories revenue of $1.80B, up 18%
  • Procedure growth 15%, with da Vinci up 14% and Ion up 31%, supporting recurring consumables demand
Filed Jul 27, 2026Full analysis →

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Bylaws strengthen advance-notice and disclosure requirements for shareholder nominations and proposals
  • Company may disregard noncompliant universal-proxy nominees, including solicitations failing the SEC’s 67% requirement

AI summaries of ISRG 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ISRG

Don't miss the next ISRG filing

  • Alerts as it files. A push when ISRG files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ISRG, by share count.
  • Ask anything. An AI agent that reads every ISRG filing and answers with sources.

ISRG alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Brosius MarkSellNov 20, 2026$407.24
Brosius MarkSellNov 19, 2026$420.95
Brosius MarkSellNov 18, 2026$430.63
Brosius MarkSellNov 17, 2026$437.33
Brosius MarkSellNov 16, 2026$444.38
LOEB GARYSellNov 10, 2026$458.15
GUTHART GARY SSellNov 4, 2026$457.34
BARRATT CRAIG HSellNov 4, 2026$460.00

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$8.4B$10.1B
Gross Profit$4.7B$5.6B$6.6B
Operating Income-$2.3B$2.9B
Net Income$1.8B$2.3B$2.9B
Gross Margin-67.5%66.0%
Op. Margin-28.1%29.3%
Net Margin-27.8%28.4%
Balance Sheet
Total Assets$15.4B$18.7B$20.5B
Equity-$16.4B$17.8B
ROE-14.1%16.0%
Per Share
EPS$5.03$6.42$7.87
Cash Flow
Operating CF-$2.4B$3.0B

Source: XBRL data in Intuitive Surgical (ISRG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ISRG share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ISRG shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202656$54.85B
Q2 202660$55.96B
Q1 202658$65.64B
Q4 202555$83.17B
Q3 202555$64.56B
Q2 202553$81.15B
Q1 202550$51.72B
Q4 202449$43.79B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 436 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ISRG filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 18, 2026--
4Nov 12, 2026--
4Nov 5, 2026--
4Nov 5, 2026--
8-KNov 2, 2026Analysis-
4Nov 2, 2026--
4Nov 2, 2026--
4Oct 28, 2026--
4Oct 26, 2026--
4Oct 26, 2026--
4Oct 26, 2026--
4Oct 26, 2026--
10-QOct 21, 2026Analysis
8-KOct 20, 2026Analysis-
4Oct 13, 2026--
4Oct 13, 2026--
4Sep 16, 2026--
4Sep 11, 2026--
4Sep 9, 2026--
4Aug 21, 2026--
4Aug 19, 2026--
4Aug 12, 2026--
4Aug 11, 2026--
4Aug 10, 2026--

Related Health Care companies

All Health Care →

ISRG SEC filings: frequently asked questions

Are ISRG insiders buying or selling?

In the last 90 days, Intuitive Surgical (ISRG) officers, directors and 10% owners reported no open-market purchases and 24 open-market sales worth $20.2 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ISRG stock?

As of September 30, 2026, the largest Intuitive Surgical (ISRG) holders among the 13F filers tracked by SignalX were BlackRock ($12.0 billion), Vanguard Capital Management LLC ($9.4 billion), State Street Corp ($6.6 billion), Invesco Ltd ($4.9 billion), T. Rowe Price Group ($4.0 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ISRG's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Intuitive Surgical (ISRG) reported revenue of $10.1 billion (up 20.5% from FY2024) and net income of $2.9 billion. Diluted EPS was $7.87. The figures come from the XBRL data in the 10-K.

What are the main risks in ISRG's latest 10-K?

In the 10-K filed February 3, 2026, Intuitive Surgical (ISRG) flagged: UK medical device regulatory changes, new post-market rules effective June 16, 2025, with additional rules expected in 2026 potentially delaying UK market approval. China anti-corruption campaign in healthcare since July 2023 causing tender cancellations, reducing system placements in 2025 versus expectations. (AI summary of the Risk Factors section.)

What did ISRG report in its latest 8-K?

Intuitive Surgical (ISRG) filed an 8-K on November 2, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 7.01 (Regulation FD Disclosure). Board expansion from 10 to 11 directors, effective January 1, 2027.

What are the latest ISRG SEC filings?

Intuitive Surgical (ISRG) filed its latest 10-K annual report on February 3, 2026, a 10-Q quarterly report on October 21, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 20, 2026.

What is ISRG's SEC CIK number?

Intuitive Surgical (ISRG)'s SEC Central Index Key (CIK) is 1035267. EDGAR lists every ISRG filing under that number.

Ask anything about ISRG

The research agent reads ISRG's filings, financials, insider trades and 13F holders, then answers with sources.